RenovoRx

RenovoRx, Inc. is a clinical-stage biopharmaceutical company, which engages in the development of therapy platform to deliver chemotherapy. Its therapy platform includes RenovoTAMP, a therapy platform designed for targeted delivery of chemotherapy enabling localized treatment of solid tumors. The company was founded by Ramtin Agah and Kamran Najmabadi in December 2009 and is headquartered in Los Altos, CA.

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

LOS ALTOS, Calif.--( BUSINESS WIRE )--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors, today announced the acceptance of four clinical data abstracts supporting its lead oncology product candidate, RenovoGem, and its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform to be presented at the 2023 ASCO Gastrointestinal Cancers Symposium (ASCO GI). The Symposium is to be held on January 19-21, 2023 in San Francisco, California and online.

RenovoRx Announces Acceptance of Four Clinical Data Abstracts at the 2023 ASCO Gastrointestinal Cancers (ASCO GI) Symposium

LOS ALTOS, Calif.--( BUSINESS WIRE )--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP) therapy platform, today announced RenovoTAMP was highlighted in two presentations delivered at the Advanced Interventional Management Symposium (AIMsymposium). RenovoTAMP is a unique therapy platform designed for targeted intra-arterial (IA) delivery of chemotherapy directly to tumors. This symposium was the 30th annual AIMsymposium and is being held November 14-17, 2022 at the New York Hilton.

RenovoRx Announces Presentations at the Advanced Interventional Management Symposium (AIMsymposium) Highlighting its Innovative RenovoTAMP® Therapy Platform for Targeted Treatment of Cancers

LOS ALTOS, Calif.--( BUSINESS WIRE )--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform, today reported its financial results for the quarter ended September 30, 2022.

RenovoRx Reports Third Quarter 2022 Financial Results

RenovoRx to Participate in ROTH Capital Deep Dive Webinar on October 27, 2022 at 1:00 P.M. ET

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP®) therapy platform, today announced management's participation in two upcoming investor conferences this month. Conferences include ROTH Inaugural Healthcare Opportunities, October 6th, and LD Micro Main Event XV, October 25th-27th. Shaun Bagai, RenovoRx's C

RenovoRx to Participate in Upcoming October 2022 Investor Conferences

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today announced Ripal Gandhi, M.D., FSIR, FSVM presented, “Trans-Arterial Micro-Perfusion Therapy for Pancreatic Cancer,” at the recent Symposium on Clinical Interventional Oncology (CIO). Dr. Gandhi is a course director for the symposiu

RenovoRx Announces Presentation at Symposium on Clinical Interventional Oncology (CIO) Highlighting its Innovative Therapy Platform for Targeted Treatment of Pancreatic Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today announced that Angela Gill Nelms has joined the company as Chief Operating Officer (“COO”). “Angela is a growth-oriented operational leader with experience in clinical trial management, a proven track record for driving innovation,

RenovoRx Appoints Angela Gill Nelms as Chief Operating Officer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMP™) therapy platform, today announced management's participation in the upcoming H.C. Wainwright 24th Annual Global Investment Conference. This conference is to be held at the Lotte New York Palace Hotel in New York City on September 12-14, 2022. Shaun Bagai,

RenovoRx to Participate in the H.C. Wainwright 24th Annual Global Investment Conference, September 12-14, 2022

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company focused on the localized treatment of difficult-to-treat solid tumors through its proprietary RenovoRx Trans-Arterial Micro-Perfusion (RenovoTAMPTM) therapy platform, today reported its financial results for the quarter ended June 30, 2022. “Over the past decade, our team has developed and refined a unique therapy platform for difficult-to-treat solid tumors by localizing and targeting chemotherapy to

RenovoRx Reports Second Quarter 2022 Financial Results

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is announcing the appointment of James Ahlers as Chief Financial Officer (CFO), effective July 15, 2022, and the addition of Ronald B. Kocak as Vice President and Controller for RenovoRx. Mr. Ahlers replaces Christopher J. Lehman, who joined RenovoRx in connection with its initial public offering and is leaving to pursue a new business opportunity. Mr. A

RenovoRx Appoints James Ahlers as Chief Financial Officer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced the launch of a new video series – The RenovoRx Story. This video series provides viewers with a unique opportunity to learn more about the Company, its leadership team, and the innovative RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfusion) therapeutic platform. Also, highlighted in the video series is the Compan

RenovoRx Launches “The RenovoRx Story” Video Series

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that they will host a webinar highlighting their RenovoTAMP™ therapy platform. The webinar, “Facing Today's Challenges in Pancreatic Cancer Treatment: Understanding RenovoRx's Trans-Arterial Micro-Perfusion Therapy Platform,” will be held on Tuesday, June 21st at 8:00 am (ET). To register for this event, click here. Speakers include Dr. Michael

RenovoRx and TIGeR-PaC Leadership to Host RenovoTAMP™ Webinar on June 21, 2022

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that it will participate in the Gateway to Translation Webinar Series hosted by the University of Cambridge's Academy of Therapeutic Sciences (CATS) on Wednesday, June 8, 2022 at 1:00 PM ET. Dr. Ramtin Agah, Chief Medical Officer and Co-Founder of RenovoRx, will present a seminar, “Localized Intra-arterial Drug Delivery for Treatment of Solid T

RenovoRx to Participate in the University of Cambridge's Academy of Therapeutic Sciences Gateway to Translation Seminar Series on June 8, 2022

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announces that it will present preclinical research supporting its planned second clinical indication, bile duct cancer, also known as cholangiocarcinoma, at the Global Embolization Oncology Symposium Technologies (GEST) 2022, today in New York City. The study demonstrates the potential utility of RenovoRx's proprietary Tran

RenovoRx to Present Preclinical Research Data Demonstrating its Innovative Therapy Platform's Potential Utility for the Treatment of Bile Duct Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced management's participation in the H.C. Wainwright Global Investment Conference on May 23-26, 2022 in Miami Beach, Florida. H.C. Wainwright Global Investment Conference Format and Dates: Hybrid, May 23-26, 2022 Location: Fountainebleau Miami Beach Hotel, Miami Beach, Florida Presenter: Shaun Bagai, CEO, to present o

RenovoRx to Participate in Upcoming H.C Wainwright Global Investment Conference in May 2022

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the quarter ended March 31, 2022. “As we report our Q1 2022 results, we acknowledge that May is Cancer Research Month. RenovoRx is fighting cancer through our innovative localized treatment of difficult-to-treat tumors via our proprietary RenovoTAMP™ (RenovoRx Trans-Arterial Micro-Perfu

RenovoRx Reports First Quarter 2022 Financial Results

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, announced today it will join the Pancreatic Cancer Action Network (PanCAN) as a Silver Sponsor of the organization's PurpleStride® Silicon Valley event to end pancreatic cancer. In order to help improve patient outcomes, RenovoRx employees and their families have united to create Team RenovoRx with a goal to support PanCAN's urgen

RenovoRx Sponsors Pancreatic Cancer Action Network's PurpleStride Event to End Pancreatic Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today is reporting its financial results for the year ended December 31, 2021. “2021 was a transformative year for RenovoRx. We successfully closed on our initial public offering and listed on the NASDAQ under ‘RNXT,'” said Shaun Bagai, CEO of RenovoRx. “Importantly, despite challenges created by the COVID-19 pandemic, we maintain

RenovoRx Reports Full Year 2021 Financial Results

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced its leadership's participation in two upcoming Investor Conferences this month. ROTH Capital Partners 34th Annual Conference Format and Dates: In person, March 13-15, 2022 Location: The Ritz Carlton Laguna Niguel Hotel, Dana Point, CA Presenters and Presentation Date/Time: Shaun Bagai, CEO, to present on Monday, Ma

RenovoRx to Participate in March 2022 Investor Conferences

NEW YORK & LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced enrollment of its first patient at one of its newest clinical sites, Columbia University New York-Presbyterian Hospital Irving Medical Center (“Columbia University”), in its ongoing TIGeR-PaC Phase 3 clinical trial. The study is evaluating the Company's therapy platform RenovoTAMP™ (RenovoRx Trans-Arteri

RenovoRx Enrolls First Pancreatic Cancer Patient at Columbia University's New York-Presbyterian Hospital Irving Medical Center in Ongoing TIGeR-PaC Phase 3 Clinical Trial

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, will host the “Delivering Therapy Where it Matters” fireside chat with CEO, Shaun Bagai, on Wednesday, February 23rd at 12 p.m. ET. During the video webinar, Mr. Bagai will discuss RenovoRx's unique approach to fighting cancer through localized and targeted chemotherapy. Additionally, he will review the Company's anticipated miles

RenovoRx to Host “Delivering Therapy Where it Matters” Fireside Chat with CEO, Shaun Bagai, on February 23rd at 12 P.M. ET

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (“RenovoRx” or the “Company”) (Nasdaq: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Dr. Ripal Gandhi, M.D., FSIR, FSVM, a Principal Investigator in the Company's Phase 3 TIGeR-PaC study, presented ‘Trans-arterial Treatment Option in Pancreas Cancer' at the recent 2022 SPECTRUM Conference. Dr. Gandhi is professor of Interventional Radiology at the Miami Cancer Institute and Miami Cardiac and V

RenovoRx Announces Presentation at the 2022 SPECTRUM Conference Highlighting Its Innovative RenovoTAMP™ Therapy for Targeted Treatment of Cancer

LOS ALTOS, Calif.--(BUSINESS WIRE)--RenovoRx, Inc. (NASDAQ: RNXT), a biopharmaceutical company and innovator in targeted cancer therapy, today announced that Shaun Bagai, Chief Executive Officer, will participate in the H.C. Wainwright Bioconnect Virtual Conference on behalf of RenovoRx. The conference will be held January 10-13, 2022. Mr. Bagai's investor presentation will be available on-demand beginning January 10th at 7:00 am EST. Management will be available during the H.C. Wainwright Bioc

RenovoRx to Present at the H.C. Wainwright Bioconnect Virtual Conference

Cortexyme Inc

Grab Holdings Ltd

NuZee, Inc.

Pioneer Power Solutions

Potential short squeeze plays have gained steam in 2021 with new retail traders looking for the next huge move. GameStop Corp (NYSE:GME) and AMC Entertainment Holdings (NYSE:AMC) are two high-profile examples of short squeezes earlier this year.

5 Short Squeeze Candidates To Watch: Pioneer Power, NuZee Remain At The Top, Grab Rejoins The Leaderboard

Newegg Commerce

TDH Hlds

PPSI, NUZE, and three other stocks are ranked highly in Fintel's Short Squeeze Screener. All three names have a score higher than 96.

News for RenovoRx Stock (RNXT)